Myriad gene patent ruling sent back to lower court

WASHINGTON (Reuters) - The U.S. Supreme Court on Monday set aside a ruling that said Myriad Genetics Inc could patent two genes linked to breast and ovarian cancers, and ordered further review by a lower court in light of a conflicting ruling in a similar case.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/RGbThMOKgh4/us-myriadgenetics-patent-idUSBRE82P0YJ20120326

internet business Current news latest news top news recent news save money